Home Cart Sign in  
Chemical Structure| 96829-58-2 Chemical Structure| 96829-58-2

Structure of Orlistat
CAS No.: 96829-58-2

Chemical Structure| 96829-58-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Orlistat is an approved reversible general lipase inhibitor with IC50 of 122 ng/mL, used to treat obesity.

Synonyms: Tetrahydrolipstatin; Ro-18-0647; Orlistat, Alli, Tetrahydrolipastatin, Tetrahydrolipstatin, THLP, Xenical

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Krueger, Nadine ; Kronenberger, Thales ; Xie, Hang ; Rocha, Cheila ; Poehlmann, Stefan ; Su, Haixia , et al.

Abstract: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has forced the development of direct-acting antiviral drugs due to the coronavirus disease 2019 (COVID-19) pandemic. The main protease of SARS-CoV-2 is a crucial enzyme that breaks down polyproteins synthesized from the viral RNA, making it a validated target for the development of SARS-CoV-2 therapeutics. New chem. phenotypes are frequently discovered in natural goods. In the current study, we used a fluorogenic assay to test a variety of natural products for their ability to inhibit SARS-CoV-2 Mpro. Several compounds were discovered to inhibit Mpro at low micromolar concentrations It was possible to crystallize robinetin together with SARS-CoV-2 Mpro, and the X-ray structure revealed covalent interaction with the protease's catalytic Cys145 site. Selected potent mols. also exhibited antiviral properties without cytotoxicity. Some of these powerful inhibitors might be utilized as lead compounds for future COVID-19 research.

Keywords: COVID-19 ; antivirals ; coronavirus ; covalent drugs ; dynamic light scattering ; inhibitors ; main protease ; natural products

Alternative Products

Product Details of Orlistat

CAS No. :96829-58-2
Formula : C29H53NO5
M.W : 495.73
SMILES Code : CC(C)CC(NC=O)C(O[C@@H](CCCCCCCCCCC)C[C@@H]([C@@H]1CCCCCC)OC1=O)=O
Synonyms :
Tetrahydrolipstatin; Ro-18-0647; Orlistat, Alli, Tetrahydrolipastatin, Tetrahydrolipstatin, THLP, Xenical
MDL No. :MFCD05662360
InChI Key :AHLBNYSZXLDEJQ-FWEHEUNISA-N
Pubchem ID :3034010

Safety of Orlistat

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H412
Precautionary Statements:P273

Isoform Comparison

Biological Activity

Target
  • Lipase

In Vitro:

Cell Line
Concentration Treated Time Description References
Huh7SR cells 102.67 ± 6.60 µM 24 hours To evaluate the inhibitory effect of orlistat on the proliferation of Huh7SR cells, the results showed that orlistat significantly inhibited the proliferation of Huh7SR cells. J Exp Clin Cancer Res. 2023 Jan 6;42(1):6.
7721SR cells 133.67 ± 6.56 µM 24 hours To evaluate the inhibitory effect of orlistat on the proliferation of 7721SR cells, the results showed that orlistat significantly inhibited the proliferation of 7721SR cells. J Exp Clin Cancer Res. 2023 Jan 6;42(1):6.
Huh7 cells 50 µM 48 hours Enhanced the cytotoxicity of sorafenib, significantly increased the sub-G1 population Int J Mol Sci. 2022 Jun 10;23(12):6501.
Huh7/SR cells 50 µM 48 hours Enhanced the cytotoxicity of sorafenib, significantly increased the sub-G1 population Int J Mol Sci. 2022 Jun 10;23(12):6501.
MS751 cells 100 µM and 250 µM 48 hours To evaluate the effect of Orlistat on the proliferation of MS751 and SiHa cells, results showed that 100 μM and 250 μM Orlistat had no significant effect on cell viability but significantly inhibited FABP5-induced FA metabolic reprogramming, invasion, EMT, and lymphangiogenesis. Theranostics. 2020 May 17;10(15):6561-6580.
SiHa cells 100 µM and 250 µM 48 hours To evaluate the effect of Orlistat on the proliferation of SiHa cells, results showed that 100 μM and 250 μM Orlistat had no significant effect on cell viability but significantly inhibited FABP5-induced FA metabolic reprogramming, invasion, EMT, and lymphangiogenesis. Theranostics. 2020 May 17;10(15):6561-6580.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Sprague-Dawley rats High-fat diet-induced obesity model Oral gavage 10 mg/kg Single dose, observed for 48 hours To evaluate the inhibitory effect of Orlistat on fat absorption, results showed that the SSPH6 group had significantly higher fat excretion than the control and Orlistat groups Int J Nanomedicine. 2018 Nov 5;13:7095-7106
BALB/c mice AOM/DSS-induced colitis-associated colon cancer model Oral 10 mg/kg/day Once daily for one week Orlistat significantly increased the survival rate, reduced tumor formation, and inhibited inflammation, hyperplasia, and tumor progression in WD-driven CAC mice by suppressing STAT3 and NF-κB signaling pathways. Cells. 2021 Aug 11;10(8):2060
Nude mice Liver cancer model Gavage 240 mg/kg 5 days/week for 21 days To evaluate the antitumor effect of orlistat in a liver cancer model, the results showed that orlistat significantly inhibited tumor growth. J Exp Clin Cancer Res. 2023 Jan 6;42(1):6.
BALB/c Nude mice LNM model Intraperitoneal injection 240 mg/kg/d Once daily for 25 days To evaluate the effect of Orlistat on FABP5-induced LNM, results showed that Orlistat significantly inhibited FABP5-induced LNM and reversed FA metabolic reprogramming. Theranostics. 2020 May 17;10(15):6561-6580.
C57BL/6 mice H22 tumor model Intraperitoneal injection 5 mg/kg Once on the first day and then every 4 days thereafter Weakened HCC tumor growth J Immunother Cancer. 2023 Nov 24;11(11):e007030

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02767531 Hyperlipoproteinemia Type I|Hy... More >>pertriglyceridemia Less << PHASE2 COMPLETED 2022-12-31 UT Southwestern Medical Center... More >> 5323 Harry Hines Blvd, Dallas, Texas, 75390-8537, United States Less <<
NCT01170806 Obesity COMPLETED 2025-04-10 LIMED (Laboratory of Investiga... More >>tion of Metabolism and Diabetes)/GASTROCENTRO/University of Campinas (UNICAMP), Campinas, Sao Paulo, 13083-878, Brazil Less <<
NCT01035333 Obesity PHASE4 COMPLETED 2025-04-11 Albany College of Pharmacy and... More >> Health Sciences, Albany, New York, 12208, United States Less <<
NCT01387243 Overweight COMPLETED 2025-12-10 -
NCT01414465 Overweight COMPLETED 2025-06-11 LIMED (Laboratory of Investiga... More >>tion of Metabolism and Diabetes)/GASTROCENTRO/University of Campinas (UNICAMP), Campinas, Sao Paulo, 13083-878, Brazil Less <<
NCT02706067 Obesity PHASE4 COMPLETED 2025-03-09 Geneve, 1211, Switzerland
NCT00152360 Obesity|Heart Diseases PHASE4 COMPLETED 2025-03-13 Healthy Heart Program/Lipid Cl... More >>inic, St. Paul's Hospital, Vancouver, British Columbia, Canada Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.02mL

0.40mL

0.20mL

10.09mL

2.02mL

1.01mL

20.17mL

4.03mL

2.02mL

References

 

Historical Records

Categories